1110018G07Rik Activators
1110018G07Rik activators encompass a diverse array of chemical compounds that enhance the functional activity of this protein through specific biochemical pathways. Forskolin, by increasing intracellular cAMP levels, activates protein kinase A (PKA), which may phosphorylate and thus alter proteins that interact with 1110018G07Rik, enhancing its activity within its specific signaling networks. Concurrently, IBMX, as a phosphodiesterase inhibitor, elevates cAMP and cGMP levels, leading to a similar enhancement of 1110018G07Rik activity by influencing proteins in the cyclic nucleotide signaling pathways. Epigallocatechin gallate, a kinase inhibitor, and Phorbol 12-myristate 13-acetate (PMA), a PKC activator, function through inhibition or activation of kinases that could phosphorylate regulatory proteins linked to 1110018G07Rik. Sphingosine-1-phosphate activates MAPK, PI3K, and PLC pathways, potentially enhancing 1110018G07Rik activity by modulating protein-protein interactions.
Further emphasizing the intricate modulation of 1110018G07Rik's activity, Anisomycin induces stress-activated protein kinases within the MAPK pathway, which could lead to an indirect enhancement of the protein's function. LY294002 and U0126 both act as inhibitors of the PI3K and MEK pathways, respectively, potentially leading to a compensatory upregulation of parallel pathways that interact with or regulate 1110018G07Rik. Similarly, SB 203580 and PD 98059 target p38 MAPK and MEK, respectively, redirecting signaling to alternate routes that could augment 1110018G07Rik's activity. The calcium ionophore A23187 increases intracellular calcium levels, activating calcium-dependent signaling that may interact with 1110018G07Rik. Lastly, Staurosporine, a broad-spectrum kinase inhibitor, could unintentionally activate pathways involving 1110018G07Rik by lowering the activity of kinases that negatively regulate proteins functioning alongside 1110018G07Rik. Collectively, these activators, through targeted biochemical interactions, serve to enhance the functional activity of 1110018G07Rik without necessitating a direct increase in its expression or activation through common pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, leading to their accumulation. The increased levels of these cyclic nucleotides may enhance the signaling pathways that phosphorylate or alter the function of 1110018G07Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate is a potent antioxidant that inhibits various protein kinases. This inhibition can alter signaling cascades, potentially leading to the activation of downstream proteins that are involved in the same pathway as 1110018G07Rik, thereby enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in a myriad of cellular functions. PKC activation can lead to the phosphorylation of proteins that may interact with or regulate 1110018G07Rik, thereby enhancing its activity by altering its interaction network. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate interacts with its receptors to activate intracellular signaling pathways including MAPK, PI3K, and PLC. Activation of these pathways could lead to enhanced functional activity of 1110018G07Rik by modulating the protein-protein interactions within these pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a potent activator of the MAPK pathway via the induction of stress-activated protein kinases. This activation can influence proteins in the MAPK pathway that may be involved in the same signaling networks as 1110018G07Rik, leading to its functional enhancement. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which can alter signaling pathways by preventing the phosphorylation of PIP2 to PIP3. The alteration in PI3K signaling may enhance the activity of 1110018G07Rik by modulating proteins and pathways that are functionally linked to it. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is part of the MAPK pathway. Inhibition of MEK can result in a compensatory response in other parallel signaling pathways that could enhance the functional activity of 1110018G07Rik by altering its protein interaction landscape. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 may lead to the redirection of signaling to alternative pathways that could enhance the functional activity of 1110018G07Rik through the modification of its signaling environment. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways. This activation can enhance the functional activity of 1110018G07Rik by influencing proteins and pathways that are calcium-sensitive and possibly interact with or regulate 1110018G07Rik. | ||||||